title: Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
authors.affiliation: Section of Nephrology, Department of Public Health, Federico II University of Naples, Naples, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Pisani
authors.affiliation: Section of Nephrology, Department of Public Health, Federico II University of Naples, Naples, Italy.
authors.forename: Eleonora
authors.initials: E
authors.lastname: Riccio
authors.affiliation: Section of Nephrology, Department of Public Health, Federico II University of Naples, Naples, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Sabbatini
mesh_terms: D056947:Enzyme Replacement Therapy; D000795:Fabry Disease / Q000188:drug therapy*; D006801:Humans; D007527:Isoenzymes / Q000008:administration & dosage*; D011994:Recombinant Proteins; D000519:alpha-Galactosidase / Q000008:administration & dosage*
chemical_list: D007527:Isoenzymes; D011994:Recombinant Proteins; C000627036:agalsidase alfa; D000519:alpha-Galactosidase; C459420:agalsidase beta